Statins and cancer: A potential link?

American Journal of Therapeutics

Volumn 17, Issue 4, 2010, Pages

  Thompson, Joseph S ^a   Sood, Aditya ^a   Arora, Rohit ^b  

^a ROSALIND FRANKLIN UNIVERSITY OF MEDICINE AND SCIENCE   (United States)

^b NCVA   (United States)

Author keywords

cancer; ENHANCE; ezetimibe; HMG CoA reductase; IDEAL; IMPROVE IT; PROSPER; SEAS; SHARP; simvastatin; Vytorin; Zetia; Zocor

Indexed keywords

EZETIMIBE; EZETIMIBE PLUS SIMVASTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PLACEBO; PRAVASTATIN; SIMVASTATIN; AZETIDINE DERIVATIVE; HYPOCHOLESTEROLEMIC AGENT;

AORTA STENOSIS; BREAST CANCER; CANCER INCIDENCE; CANCER MORTALITY; CANCER RISK; CEREBROVASCULAR DISEASE; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DRUG ACTIVITY; DRUG EFFECT; HUMAN; HYPERCHOLESTEROLEMIA; ISCHEMIC HEART DISEASE; NEOPLASM; NONHUMAN; OBESITY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REVIEW; CHEMICALLY INDUCED;

ANTICHOLESTEREMIC AGENTS; AZETIDINES; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERCHOLESTEROLEMIA; NEOPLASMS;

EID: 77954997066     PISSN: 10752765     EISSN: None     Source Type: Journal    
DOI: 10.1097/MJT.0b013e31819df9cd     Document Type: Review

References (36)

1. Jones S. Hypercholesterolemia statistics for the US. Available at: http://ezinearticles.com/?Hypercholesterolemia- Statistics-For-The-U.S.&id= 641689. July 2007.
2. Levinsky RJ, Brown H. Statins. Too many people are taking them (and they're doing far less good than you think). Lancet. 2007; 69:268-269. Available at: http://www. healthy.net/scr/news.asp?Id=8950.
3. Pederson T. Results from the SEAS (Simvastatin and Ezetimibe in Aortic Stenosis) Study. Available at: www. presseportal.de/text/story.htx?nr=1232600. July 2008.
4. Rossebø AB, Pedersen TR, Boman K, et al. Intensive lipid lowering with simvastatin and ezetimibe in aortic stenosis. N Engl J Med. 2008;359:1343-1356.
5. Kastelein JJP, Akdim F, Stroes ESG, et al. Simvastatin with or without ezetimibe in familial hypercholesterolemia. N Engl J Med. 2008;358:1431-1443.
6. Telford DE, Sutherland BG, Edwards JY, et al. The molecular mechanisms underlying the reduction of LDL apoB-100 by ezetimibe plus simvastatin. Journal of Lipid Research. 2007;48:699-708.
7. Stancu C, Sima A. Statins: mechanism of action and effects. J Cell Mol Med. 2001;5:378-387.
8. Jackevicius CA, Tu JV, Ross JS, et al. Use of ezetimibe in the United States and Canada.NEngl J Med. 2008;358:1819-1828.
9. Arcia-Calvo M, Lisnock J, Bull HG, et al. The target of ezetimibe is Niemann-Pick C1-Like 1 (NPC1L1). Proc Natl Acad Sci U S A. 2005;102:8132-8137.
10. Davis HR, Veltri EP. Zetia: inhibition of Niemann-Pick C1 Like 1 (NPC1L1) to reduce intestinal cholesterol absorption and treat hyperlipidemia. J Atheroscler Thromb. 2007; 14:99-108.
11. Ge L, Wang J, Qi W, et al. The cholesterol absorption inhibitor ezetimibe acts by blocking the sterol-induced internalization ofNPC1L1. Cell Metabolism. 2008;7:508-519.
12. Robinson JG, Davidson M. Is it over for ezetimibe? Expert Rev Cardiovasc Ther. 2008;6:781-783.
13. Temel RE, Tang WM, Yinyan R, et al. Hepatic Niemann- Pick C1-like 1 regulates biliary cholesterol concentration and is a target of ezetimibe. J Clin Invest. 2007;117:1968-1978.
14. Braun, A, Yesilaltay A, Acton S, et al. Inhibition of intestinal absorption of cholesterol by ezetimibe or bile acids by SC-435 alters lipoprotein metabolism and extends the lifespan of SR-BI/apoE double knockout mice. Atherosclerosis. 2008;198:77-84.
15. Spener F. Ezetimibe in search of receptor(s)-still a neverending challenge in cholesterol absorption and transport. Biochem Biophys Acta. 2007;1771:1113-1116.
16. Repa JJ, Turley SD, Quan G, et al. Delineation of molecular changes in intrahepatic cholesterol metabolism resulting from diminished cholesterol absorption. Journal of Lipid Research. 2005;46:779-789.
17. Taylor AJ. Given the ENHANCE trial results, ezetimibe is still unproven. Cleve Clin J Med. 2008;75:497-506.
18. Rossebø AB, Pedersen TR, Allen C, et al. Design and baseline characteristics of the Simvastatin and Ezetimibe in Aortic Stenosis (SEAS) Study. Am J Cardiol. 2007;99:970-973.
19. Jones PH. Low cholesterol, statins, and cancer risk: déjà vu all over again. Cardiology Review Online. http://www. cardiologyreviewonline. com/issues/articles/2007-09-03.asp. September 2007.
20. Sherwin RW, Wentworth DN, Cutler JA, et al. Serum cholesterol levels and cancer mortality in 361,662 men screened for the Multiple Risk Factor Intervention Trial. JAMA. 1987;257:943-948.
21. Newman TB, Hulley SB. Carcinogenicity of lipid-lowering drugs. JAMA. 1996;275:55-60.
22. Alsheikh-Ali AA, Maddukuri PV, Han H, et al. Effect of the magnitude of lipid lowering on risk of elevated liver enzymes, rhabdomyolysis and cancer. J Am Coll Cardiol. 2007;50:409-418.
23. Shepherd J, Blauw GH, Murphy MB, et al. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomized controlled trial. Lancet. 2002;360:1623-1630.
24. Agalliu I, Salinas CA, Hansten PD, et al. Statin use and risk of prostate cancer: results from a population-based epidemiologic study. Am J Epidemiol. 2008;168:250-260.
25. Borgquist S, Djerbi S, Ponten F, et al. HMG-CoA reductase expression in breast cancer is associated with a less aggressive phenotype and influenced by anthropometric factors. Int J Cancer. 2008;123:1146-1153.
26. Knekt P, Reunanen A, Aromaa A, et al. Serum cholesterol and risk of cancer in a cohort of 39,000 men and women. J Clin Epidemiol. 1998;41:519-530.
27. Cannon CP. The IDEAL cholesterol. JAMA. 2005;294: 2492-2494.
28. Bonovas S, Filioussi K, Tsavaris N, et al. Statins and cancer risk: a literature-based meta-analysis and metaregression analysis of 35 randomized controlled trials. J Clin Oncol. 2006;24:4808-4817.
29. Dale KM, Coleman CI, Henyan NN, et al. Statins and cancer risk: a meta-analysis. JAMA. 2006;295:74-80.
30. Boudreau DM, Yu O, Miglioretti DL, et al. Statin use and breast cancer risk in a large population-based setting. Cancer Epidemiol Biomarkers Prev. 2007;16:416-421.
31. Alsheikh-Ali AA, Trikalinos TA, Kent DM, et al. Statins, low-density lipoprotein cholesterol, and risk of cancer. J Am Coll Cardiol. 20 Aug 2008 [Epub ahead of print].
32. Peto R, Emberson J, Landray M, et al. Analyses of cancer data from three ezetimibe trials. N Engl J Med. 2008;359: 1357-1366.
33. Cauley JA, McTiernan A, Rodabough RJ, et al. Statin use and breast cancer: prospective results from the Women's Health Initiative. J Natl Cancer Inst. 2006;98:700-707.
34. Platz EA, Leitzmann MF, Visvanathan K, et al. Statin drugs and risk of advanced prostate cancer. J Natl Cancer Inst. 2006;98:1819-1825.
35. Baigent C, Landry M. Study of Heart and Renal Protection (SHARP). Kidney Int Suppl. 2003;84:207-210.
36. Rosenhek R, Baumgartner H. Aortic sclerosis, aortic stenosis and lipid-lowering therapy. Expert Rev Cardiovasc Ther. 2008;6:385-390.